免疫检查点抑制剂治疗卵巢癌的研究进展

Research progress of immunocheckpoint inhibitors in the treatment of ovarian cancer

免疫检查点抑制剂通过抑制免疫系统中抑制性信号通路免疫检查点发挥生物学作用,在妇科肿瘤中的应用尚处于早期阶段,是目前临床研究的一个活跃领域,其治疗成功的关键在于识别潜在患者并从中获益。应用免疫检查点抑制剂抗CTLA-4抗体、抗PD-1/PD-L1抗体治疗卵巢癌,单药应答率10%~15%,联合治疗应答率有所提高。文章综述当前研究的最新临床数据结果,以期对当前治疗给予用药指导,并简要展望未来。

Immunosuppressive checkpoint inhibitors play a biological role by inhibiting the immunosuppressive signal pathway in the immune system.Their application in gynecological tumors is still at an early stage,which is an active field of clinical research at present.The key to the success of their treatment lies in identifying potential patients and benefiting from them.Anti CTLA-4 and anti PD-1/PDL-1 antibody were used to treat ovarian cancer.The response rate of single drug was 10%~15%,and the response rate of combined treatment was improved.This article reviews the latest clinical data of the current research,in order to give medication guidance for the current treatment,and briefly looks forward to the future.